Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
Open Access
- 2 September 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 35 (12), 1257-1270
- https://doi.org/10.1007/s40273-017-0558-5
Abstract
Background New immuno-oncology (I-O) therapies that harness the immune system to fight cancer call for a re-examination of the traditional parametric techniques used to model survival from clinical trial data. More flexible approaches are needed to capture the characteristic I-O pattern of delayed treatment effects and, for a subset of patients, the plateau of long-term survival. Objectives Using a systematic approach to data management and analysis, the study assessed the applicability of traditional and flexible approaches and, as a test case of flexible methods, investigated the suitability of restricted cubic splines (RCS) to model progression-free survival (PFS) in I-O therapy. Methods The goodness of fit of each survival function was tested on data from the CheckMate 067 trial of monotherapy versus combination therapy (nivolumab/ipilimumab) in metastatic melanoma using visual inspection and statistical tests. Extrapolations were validated using long-term data for ipilimumab. Results Modelled PFS estimates using traditional methods did not provide a good fit to the Kaplan–Meier (K–M) curve. RCS estimates fit the K–M curves well, particularly for the plateau phase. RCS with six knots provided the best overall fit, but RCS with one knot performed best at the plateau phase and was preferred on the grounds of parsimony. Conclusions RCS models represent a valuable addition to the range of flexible approaches available to model survival when assessing the effectiveness and cost-effectiveness of I-O therapy. A systematic approach to data analysis is recommended to compare the suitability of different approaches for different diseases and treatment regimens.Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 28 references indexed in Scilit:
- Statistical issues and challenges in immuno-oncologyJournal for ImmunoTherapy of Cancer, 2013
- The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation studyJournal of Statistical Computation and Simulation, 2013
- Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic EvaluationMedical Decision Making, 2013
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level DataMedical Decision Making, 2013
- The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer TherapiesHealth Outcomes Research in Medicine, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaThe New England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Estimating and modeling the cure fraction in population-based cancer survival analysisBiostatistics, 2006